

SECTION-1: Identification of the substance / mixture and the company / undertaking

Catalogue Number	CS-ED-00088
Product Name	Clidinium Bromide Impurity
CAS No.	6581-06-2
Category	Impurity
Synonyms	1-azabicyclo[2.2.2]octan-3-yl 2-hydroxy-2,2-diphenylacetate; 3-Quinuclidinyl benzilate; Chinuclidylbenzilate; 3-quinuclidinylbenzilate; 3-Quinuclidyl benzilate; 3-quinuclidinyl-benzilate
Brand	Clearsynth Labs Ltd.
Identified uses	Laboratory Chemicals
Uses advised against	Not available
Company	Clearsynth Labs Ltd. Mumbai, India
Emergency Phone #	+91-22-245045900
REACH No.	Not available

SECTION 2: Hazards identification

Disclaimer: This is sample MSDS. Please email sales@clearsynth.com for more details.

2.1 Classification of the substance or mixture-Regulation (EC) No 1272/2008:

Not available

2.2 Label Elements

Signal Word: Warning



Hazard Statement(s)

Code	Statement
H300	Not available

Precautionary Statement(s)

Code	Statement
P264	Wash hands thoroughly after handling.
P270	Not available
P301+P316	Not available
P321	Specific treatment (see ... on this label).
P330	Not available
P405	Store locked up.
P501	Dispose of contents/container in accordance with local/regional/national/international regulation

SECTION 3: Composition / information on ingredients

3.1 Substance

Component : Clidinium Bromide Impurity

CAS Number : 6581-06-2

Molecular Formula : C₂₁H₂₃NO₃

Molecular Weight : 337.41

Parent Chemical : Clidinium Bromide

Synonyms : 1-azabicyclo[2.2.2]octan-3-yl 2-hydroxy-2,2-diphenylacetate; 3-Quinuclidinyl benzilate;

Chinuclidylbenzilate; 3-quinuclidinylbenzilate; 3-Quinuclidyl benzilate; 3-quinuclidinyl-benzilate

Concentration : Not available

SECTION 4: First aid measures

Not available

SECTION 5: Firefighting measures

Not available

SECTION 6: Accidental release measures

Not available

SECTION-7: Handling and storage

Not available

SECTION 8: Exposure controls / personal protection

Not available

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Test	Result
Appearance	No data available
IR spectrum	No data available
pH	No data available
Solubility	No data available

Property	Value
a) Physical State	No data available
b) Color	No data available
c) Odor	No data available
d) pH	No data available
e) Vapour Pressure	No data available
f) Viscosity	No data available
g) Initial Boiling Point and boiling range	No data available
h) Melting Point / Freezing Point	No data available
i) Auto Ignition Temperature	No data available
j) Flash Point	No data available
k) Explosion Limit, Lower	No data available
l) Explosion Limit, Upper	No data available
m) Decomposition Temperature	No data available
n) Loss on Drying	No data available
o) Relative Density	No data available
p) Solubility (in DMSO)	No data available
q) Oxidizing Properties	No data available

SECTION 10: Stability and reactivity

Not available

SECTION 11: Toxicological information

11.1 Information on toxicological effects

- Acute toxicity: /SIGNS AND SYMPTOMS/ BZ toxicity, which might occur by inhalation, ingestion, or skin absorption, is an anticholinergic syndrome consisting of a combination of signs and symptoms that might include hallucinations; agitation; mydriasis (dilated pupils); blurred vision; dry, flushed skin; urinary retention; ileus; tachycardia; hypertension; and elevated temperature (>101deg F). The onset of incapacitation is dose-dependent. It might occur as early as 1 hour after exposure and continue up to 48 hours For more Human Toxicity Excerpts (Complete) data for BZ (22 total), please visit the HSDB record page.
- Skin corrosion/irritation: No data available.
- Serious eye damage/eye irritation: No data available.
- Respiratory or skin sensitization: No data available.
- Germ cell mutagenicity: No data available.
- Carcinogenicity: No data available.
- Reproductive toxicity: No data available.
- STOT-single exposure: No data available.
- STOT-repeated exposure: /LABORATORY ANIMALS: Subchronic or Prechronic Exposure/ In a 42-day exposure of dogs administered BZ intravenously at 100 ug/kg, slight pathological changes were observed in the gastrointestinal tract (ulceration and bloody stool) in 50% of the exposed dogs and 25% of the controls. There was a slight increase in kidney weight and a slight decrease in liver and spleen weights. There were no changes in white-blood-cell or sodium measurements
- Aspiration hazard: No data available.

Likely routes of exposure

- See Inhalation Exposure. - If liquid containing QNB is splashed in the eye, irritation and inflammation of the membranes (conjunctivitis) may occur.

Symptoms related to the physical, chemical and toxicological characteristics

- Mild to moderate intoxication: "Anticholinergic toxidrome" of elevated body temperature (hyperthermia), dry mouth (xerostomia), dry skin, low urine output, flushing (redness) of skin, dilated pupils (mydriasis), inability to focus on near objects, blurred vision, and rapid heart rate (later a normal or slow heart rate). Other effects include disorientation, altered level of consciousness, misperceptions and difficulty in interpretation (delusions, hallucinations), poor judgment and insight (denial of illness), short attention span, distractibility, impaired short-term memory, slurred speech, involuntary repetition of behaviors (perseveration), loss of coordination (ataxia), variability in behavior (e.g., between quiet and restless states), and muscle weakness. - Severe intoxication: Dose-dependent decrease in consciousness level (drowsiness through sedation to stupor and coma), hallucinations and combative agitation, serious alterations in heart rhythm (cardiac arrhythmias), and serious alterations in levels of ions in biological fluids (electrolyte disturbances).

SECTION 12: Ecological information

Not available

SECTION 13: Disposal considerations

Not available

SECTION 14: Transport information

Not available

SECTION 15: Regulatory information

Not available

SECTION 16: Other information

Not available

DISCLAIMER

This MSDS is system-generated. Please verify and confirm all data, statements, and values with the Support Team before use or distribution.